Similar Articles
Lessons learned and paths forward: Navigating the social landscape of multiple sclerosis care in the second wave of COVID-19
Nazire Pınar Acar Ozen, Dilara Cilizoglu, Bernanur Toprak, Nartan Demirok, Yeliz Salci, Rana Karabudak, Umut Beşpinar, Aslı Tuncer
DOI: 10.55697/tnd.2025.347
Alemtuzumab-induced antineutrophil cytoplasmic antibody-associated nephritis in a patient with multiple sclerosis
Furkan Sarıdaş, Saide Elif Güllülü Boz, Belkıs Nihan Coşkun, Emine Rabia Koç, Abdulmecit Yıldız, Berna Aytaç Vuruşkan, Ömer Faruk Turan
DOI: 10.55697/tnd.2024.238
Redefining multiple sclerosis: 2024 McDonald diagnostic criteria
Hazal Ceren Manazoğlu, Murat Kürtüncü
DOI: 10.55697/tnd.2025.500
Association of lifestyle, psychological, and biological risk factors with multiple sclerosis: A case-control study
Rahim Aliyev, Aytan Mammadbayli, Rana Shiraliyeva
DOI: 10.55697/tnd.2025.494
Long-term cladribine experience in relapsing-remitting multiple sclerosis
Ömer Faruk Turan, Furkan Sarıdaş, Emine Rabia Koç
DOI: 10.55697/tnd.2025.293
Association between urinary symptoms, quality of life, and pelvic floor function in females diagnosed with multiple sclerosis
Seda Kılıç, Ayşe Neriman Yılmaz, Murat Terzi
DOI: 10.55697/tnd.2025.323
Audiovestibular findings according to the subtypes of multiple sclerosis
Fatmanur Uysal, Selim S. Erbek, Alper Köycü, Osman Halit Çam, Meliha Güleryüz
DOI: 10.55697/tnd.2025.442
Development of restless legs syndrome severity prediction models for people with multiple sclerosis using machine learning
Ergi Kaya, Murat Emeç, Asiye Tuba Özdoğar, Ela Simay Zengin, Hilal Karakaş, Seda Daştan, Cavid Baba, Mehmet Hilal Özcanhan, Serkan Özakbaş
DOI: 10.55697/tnd.2025.511
Nationwide prescription big data: An evaluation of injectable, oral, and monoclonal antibody disease-modifying therapies in multiple sclerosis
Esra Taşkıran, Bilgin Öztürk, Naim Ata, Şuayip Birinci
DOI: 10.55697/tnd.2026.622